ReviewCold Spring Harbor perspectives in medicine2015
Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis.
Review in Cold Spring Harbor perspectives in medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06700577 (Prevalence of Multidrug Resistant Tuberculosis by Xpert MTB/RIF Ultra and Xpert XDR Assay Among Newly Diagnosed Cases), which is not on this map. Cited by 329 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence of Multidrug Resistant Tuberculosis by Xpert MTB/RIF Ultra and Xpert XDR Assay Among Newly Diagnosed Cases
Who cites it
329 citing papers in PubMed, 5 syntheses or guidelines pooled it, 767 citations in OpenAlex.
- Global and regional trends in multidrug- or rifampicin-resistant tuberculosis, 2000-2024 with forecasts to 2030: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Nanoparticles as an Alternative Strategy for the Rapid Detection ofIET nanobiotechnology · 2025Pooled it
- The Prevalence of Mycobacterium Tuberculosis Infection in Saudi Arabia: A Systematic Review and Meta-analysis.Journal of epidemiology and global health · 2024Pooled it
- Association between HIV and acquisition of rifamycin resistance with first-line TB treatment: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- A systematic review of economic evaluations of pharmacological treatments for active tuberculosis.Frontiers in public health · 2024Pooled it
- Baseline determinants of adherence for drug-sensitive TB treatment in a South African prospective cohort: a focus on HIV infection and anti-retroviral therapy, clinical care access, and TB stigma.BMC infectious diseases · 2026Trial
- Computational introspection of impact of mutation A90V and A90E in DNA gyrase a of Mycobacterium tuberculosis in developing resistance against Delafloxacin.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Article
- Bioinspired peptide cyclisation enables exploration of cytochrome P450 catalysed sequential oxidation in rufomycin biosynthesis.Chemical science · 2026Article
- Free energy perturbation and machine learning-assisted identification of novel molecules for the Mycobacterium tuberculosis KasA protein: a fragment-based drug design approach.Molecular diversity · 2026Article
- Contributions of Community Advisory Board and Experience of Study Participants in TB/MDR-TB Clinical Trial Management in Addis Ababa, Ethiopia: A Qualitative Study.Developing world bioethics · 2026Article
- The MEG3/miR-133b regulatory axis in exosomes influences macrophage responses to drug-resistant mycobacterium tuberculosis.Archives of microbiology · 2026Article
- Rapid detection of treatment-emergent resistance to bedaquiline and pretomanid inMicrobiology spectrum · 2026Article
- Human resources management for communicable diseases in Afghanistan.Human resources for health · 2026Article
- Applying prior knowledge of regulatory signaling to investigate macrophage cAMP dynamics during Mycobacterium tuberculosis infection.Scientific reports · 2026Article
- A Decade of Unfavorable Outcomes in Pulmonary Tuberculosis: Proportion and Factors Associated in Kelantan, Malaysia.Infectious diseases & clinical microbiology · 2026Article
- Retractions in tuberculosis research: analyzing patterns, reasons, and temporal trends from 1993 to 2023.Archives of microbiology · 2026Article
- Molecular Interplay of Brucellosis and Tuberculosis: Insights into Telomere Biology, Oxidative Stress, and Drug Resistance Mechanisms.Diseases (Basel, Switzerland) · 2026Review
- Novel Anti-Microbial Peptides Design and Screening Against the KatG Using Molecular Docking and MD Simulation.Probiotics and antimicrobial proteins · 2026Article
- Coarse-Grained Simulations of Mycobacterial Outer Membranes Reveal Fluidity-Dependent PDIM Redistribution across Different Lipid Environments.Biomacromolecules · 2026Article
269 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The continuing spread of drug-resistant tuberculosis (TB) is one of the most urgent and difficult challenges facing global TB control. Patients who are infected with strains resistant to isoniazid and rifampicin, called multidrug-resistant (MDR) TB, are practically incurable by standard first-line treatment. In 2012, there were approximately 450,000 new cases and 170,000 deaths because of MDR-TB. Extensively drug-resistant (XDR) TB refers to MDR-TB strains that are resistant to fluoroquinolones and second-line injectable drugs. The main causes of the spread of resistant TB are weak medical systems, amplification of resistance patterns through incorrect treatment, and transmission in communities and facilities. Although patients harboring MDR and XDR strains present a formidable challenge for treatment, cure is often possible with early identification of resistance and use of a properly designed regimen. Community-based programs can improve treatment outcomes by allowing patients to be treated in their homes and addressing socioeconomic barriers to adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.